GSK takes fight to AZ/Merck & Co with first-line ovarian can...

The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class

Merck builds case for six-week Keytruda dosing as FDA starts...

Immuno-oncology latecomer GSK shows off PD-1 drug data

AbbVie, J&J embed Imbruvica deeper in CLL therapy with new a...

BMS gets an important win for Opdivo combination in kidney c...